Currently out of the existing stock ratings of Tim Anderson, 37 are a BUY (38.95%), 45 are a HOLD (47.37%), 13 are a SELL (13.68%).

Tim Anderson

Work Performance Price Targets & Ratings Chart

Analyst Tim Anderson, currently employed at BAML, carries an average stock price target met ratio of 86.34% that have a potential upside of 35.92% achieved within 223 days.

Tim Anderson’s has documented 186 price targets and ratings displayed on 17 stocks. The coverage is on Industrials, Healthcare sectors.

Most recent stock forecast was given on BMY, Bristol-Myers Squibb Company at 10-Jul-2026.

Wall Street Analyst Tim Anderson

Analyst best performing recommendations are on MLYS (MINERALYS THERAPEUTICS, COMMON STOCK).
The best stock recommendation documented was for MLYS (MINERALYS THERAPEUTICS, COMMON STOCK) at 8/28/2025. The price target of $43 was fulfilled within 46 days with a profit of $27.78 (182.52%) receiving and performance score of 39.68.

Average potential price target upside

of $100.42 (23.89%) on LLY (ELI LILLY AND COMPANY).
of $68.93 (9.8%) on REGN (REGENERON PHARMACEUTICALS).
of $39.59 (95.85%) on APGE (APOGEE THERAPEUTICS, COMMON STOCK).

HUBG Hub Group LLY Eli Lilly and Company MRK Merck mpany PFE Pfizer ABBV AbbVie AMGN Amgen BIIB Biogen BMY Bristol-Myers Squibb Company GILD Gilead Sciences JNJ Johnson & Johnson MRNA Moderna REGN Regeneron Pharmaceuticals AZN AstraZeneca PLC ADR AMLX Amylyx Pharmaceuticals APGE Apogee Therapeutics, Common Stock MLYS Mineralys Therapeutics, Common Stock NVS Novartis AG ADR

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Chris Kuhn (BENCHMARK)